Alnylam Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 113   

Articles published

ALNY 107.38 +2.13 (2.02%)
price chart
Alnylam Pharmaceuticals, Inc. Earnings: 100% Positive (Data)
In addition to patisiran and revusiran, Alnylam Pharmaceuticals has five other drugs in earlier stage development and plans for two more to enter the clinic by the end of the year.
Alnylam Pharmaceuticals, Inc. Price Target Update  News Watch International
Biotech Stocks Roundup: Alnylam Pharmaceuticals Inc (ALNY), Relypsa Inc ...  Investor Wired
Alnylam Pharmaceuticals, Inc. Short Interest Update
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), A increase of 225,830 shares or 6.6% was observed in the short interest of Alnylam Pharmaceuticals, Inc. The interest on November 13,2015 came in at 3,635,091 shares and as per the average daily trading of ...
Alnylam Pharmaceuticals (ALNY) - Analysts' Recent Ratings Changes  Dakota Financial News
Alnylam Pharmaceuticals Incorporated (ALNY) Shorted Shares Increased 6.62 ...  Voice Chronicle
Company Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Rally 0.04%
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rose by 0.04% in the past week and 28.73% for the last 4 weeks.
A Reversal for Alnylam Pharmaceuticals, Inc. Is Not Near. Professional ...
Alnylam Pharmaceuticals CEO John Maraganore Sells 58690 Shares (ALNY)  MidSouth Newz
Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock
Compared to other companies in the Biotechnology industry and the overall market, ALNYLAM PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
Alnylam Pharmaceuticals Keeping Multiple High-Potential Programs Moving Forward
Alnylam Pharmaceuticals (NASDAQ:ALNY) has taken its share of drubbing, with the shares down about 20% since my last piece on concerns about the implications of potential drug pricing reforms on its largely orphan drug-focused pipeline, as well as ...
Alnylam Pharmaceuticals, Inc. (ALNY) Files Form 4 Insider Selling : Kevin P ...  Insider Trading Report
Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Barbarian At The Gate ...
TheStreet Quant Ratings rates Alnylam Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the ...
Alnylam Pharmaceuticals, Inc. (ALNY) Files Form 4 Insider Selling : John ...
Alnylam Pharmaceuticals, Inc. (ALNY): John Maraganore , Chief Executive Officer of Alnylam Pharmaceuticals, Inc. sold 58,690 shares on Nov 20, 2015. The Insider selling transaction was disclosed on Nov 20, 2015 to the Securities and Exchange ...
Can Alnylam Pharmaceuticals, Inc.'s Tomorrow be Different? The Stock ...
Insider Selling: Alnylam Pharmaceuticals CEO Sells 58690 Shares of Stock (ALNY)  Dakota Financial News
Price Target Update on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): 7 analysts have set the short term price target of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) at $148.57. The standard deviation of short term price target has been estimated at $26.99, implying that the ...
Update: Analysts Rate Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY) a 1 ...  The Bulletin
Alnylam Pharmaceuticals Receives $145.27 Average PT from Brokerages (NASDAQ:ALNY)
Alnylam Pharmaceuticals logo Alnylam Pharmaceuticals (NASDAQ:ALNY) has been given a consensus rating of “Buy” by the sixteen analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell ...
Alnylam Pharmaceuticals, Inc. Analyst Rating Update
As many as 9 brokerage firms have rated Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) at 1.56. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term.
Company Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Rally 7.83%  American Trade Journal
Stock Ratings and Sentiment Update on Alnylam Pharmaceuticals, Inc. (NASDAQ ...  Investor Newswire